Vasodilating antihypertensive drugs induce hypotension with reflex tachycardia, renin release, and fluid and electrolyte retention. Propranolol can impair this renin release. The studies described here were designed to determine the hemodynamic role of vasodilatory drug-induced renin release and inhibition thereof by propranolol in two animals models, the unanesthetized, normotensive and the unanesthetized, genetically hypertensive rat. In studies with normotensive rats, propranolol impaired renin release and tachycardia resulting from hydralazine and minoxidil and potentiated their hypotensive action. Two additional interventions against the renin-angiotensin system were used in evaluating the mechanism of this potentiation. One was removal of the renin source by nephrectomy, and the second was blockade of angiotensin's vasoconstrictor action using a selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II (previously known as P113)).. Both interventions potentiated vasocilatory drug hypotension, as did propranolol, but did not prevent reflex tachycardia. When combined with saralasin propranolol did not add to protentiation by this peptide. A similar pattern of blood pressure decrement and potentiation was seen in genetically hypertensive rats when propranolol or saralasin treatment preceded hydralazine. Propranolol was demonstrated to block hydralazine-induced increases in serum renin activity in genetically hypertensive rats. We conclude that hypotensive potentiation of vasocilating drugs by propranolol in these animal models is mediated to a large extent by impairment of renin release. Persistence of hypotensive tachycardia after nephrectomy and after […] A B S T R A C T Vasodilating antihypertensive drugs induce hypotension with reflex tachycardia, renin release, and fluid and electrolyte retention. Propranolol can impair this renin release. The studies described here were designed to determine the hemodynamic role of vasodilatory drug-induced renin release and inhibition thereof by propranolol in two animals models, the unanesthetized, normotensive and the unanesthetized, genetically hypertensive rat. In studies with normotensive rats, propranolol impaired renin release and tachycardia resulting from hydralazine and minoxidil and potentiated their hypotensive action. Two additional interventions against the renin-angiotensin system were used in evaluating the mechanism of this potentiation. One was removal of the renin source by nephrectomy, and the second was blockade of angiotensin's vasoconstrictor action using a selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II [previously known as P-113]). Both interventions potentiated vasodilatory drug hypotension, as did propranolol, but did not prevent reflex tachycardia. When combined with saralasin propranolol did not add to protentiation by this peptide. A similar pattern of blood pressure decrement and potentiation was seen in genetically hypertensive rats when propranolol or saralasin treatment preceded hydralazine. Propranolol was demonstrated to block hydralazineinduced increases in serum renin activity in genetically hypertensive rats. We conclude that hypotensive potentiation of vasodilating drugs by propranolol in these animal models is mediated to a large extent by impair-
A B S T R A C T Vasodilating antihypertensive drugs induce hypotension with reflex tachycardia, renin release, and fluid and electrolyte retention. Propranolol can impair this renin release. The studies described here were designed to determine the hemodynamic role of vasodilatory drug-induced renin release and inhibition thereof by propranolol in two animals models, the unanesthetized, normotensive and the unanesthetized, genetically hypertensive rat. In studies with normotensive rats, propranolol impaired renin release and tachycardia resulting from hydralazine and minoxidil and potentiated their hypotensive action. Two additional interventions against the renin-angiotensin system were used in evaluating the mechanism of this potentiation. One was removal of the renin source by nephrectomy, and the second was blockade of angiotensin's vasoconstrictor action using a selective angiotensin antagonist, saralasin (1-Sar-8-Ala-angiotensin II [previously known as P-113]). Both interventions potentiated vasodilatory drug hypotension, as did propranolol, but did not prevent reflex tachycardia. When combined with saralasin propranolol did not add to protentiation by this peptide. A similar pattern of blood pressure decrement and potentiation was seen in genetically hypertensive rats when propranolol or saralasin treatment preceded hydralazine. Propranolol was demonstrated to block hydralazineinduced increases in serum renin activity in genetically hypertensive rats. We conclude that hypotensive potentiation of vasodilating drugs by propranolol in these animal models is mediated to a large extent by impair-INTRODUCTION When combined with propranolol, the vasodilatory drugs hydralazine and minoxidil yield an effective antihypertensive combination with few adverse effects (1) (2) (3) (4) . Vasodilatory drugs induce renin release both in man (5) (6) (7) and in animals (8) , and a large portion of this renin release can be blocked by propranolol in animals (8) . These studies were designed to determine if the increment in angiotensin formation resulting from an increase in serum renin activity limits vasodilatory drug hypotension, and, if so, does propranolol impairment of renin release contribute significantly to blood pressure lowering by the drug combination. After the administration of hydralazine or minoxidil, cardiovascular indices (heart rate and systolic blood pressure) Systolic blood pressure of normotensive rats was recorded with an automatic tail cuff (Narco Bio-Systems, Inc., Houston, Tex.), pneumatic pulse transducer (Narco), and an electrosphygmograph coupler (Narco 7211) with a Narco DMP-48 physiograph. Heart rate was obtained from the tail pulse with this system. For comparable results in each figure, the same six animals were used in each experiment with 1-day washout periods interposed between each treatment with one exception; experiments in nephrectomized normotensive animals were done the day after surgery (18 h). Serum renin activity at this time was 0.1 ng/ml/h in six rats as compared to the normal control value of 2.5 ng (see Table I ).
The lack of effect of sham operation, in lieu of nephrectomy, was reported previously for similar hemodynamic studies involving anesthesia (9) . Since the warming exposure necessary for the indirect measurement of blood pressure proved to be too stressful for the genetically hypertensive rats, direct mean arterial pressure was measured in genetically hypertensive rats using an indwelling Week's catheter placed in the descending aorta (10), a pressure transducer (Narco RP-1500), a strain gauge coupler (Narco 7172) and a Narco DMP-48 physiograph. The rats were used in hemodynamic experiments 5 days after surgery.
Biochemical experiments with genetically hypertensive rats (Table I) were performed with the same time sequences as with normotensive rats in Fig. 2 . The technique 'Pettinger, W. A., K. Keeton, and K. Tanaka. 1974 . The radioimmunoassay and pharmacokinetics of saralasin (1-Sar-8-Ala-angiotensin II) in the rat and hypertensive man.
Clin. Pharmacol. Ther. In press. of blood collection from unanesthetized rats, the measurement of serum renin activity (SRA) 2 by radioimmunoassay, and the measurement of plasma propranolol levels, were as previously described (8) . Statistical significance in the hemodynamic experiments was determined by using Student's t test. RESULTS
Biochemical studies with normotensive rats. Characteristics of vasodilatory drug-induced renin release and the effect of propranolol on this mechanism of renin release are summarized in Figs. 1 and 2 . Fig. 1 gives the chronology of renin release by minoxidil and hydralazine as well as the log dose-response curve for the two drugs. Parts of these data were reported previously (8) and are extended and summarized here for ready comparison with hemodynamic events. The ability of different doses of propranolol to impair renin release caused by these two vasodilators are shown in Fig. 2 Hemodynamic studies with normotensive rats. 1 mg/ kg hydralazine (which results in a sevenfold increase in SRA) lowered average systolic blood pressure by 21% and markedly increased the heart rate ( Fig. 3) . In the same rats propranolol (1.5 mg/kg) lowered blood pressure by 5% and heart rate by 13%. Combined treatment with propranolol and hydralazine lowered blood pressure by an average of 39% and mitigated the tachycardia caused by hydralazine alone.
Results of hemodynamic studies with the combination of minoxidil and propranolol (Fig. 4) are similar except for the prolonged duration of action with minoxidil. Propranolol and minoxidil reduced blood pressure by 3 and 15%, respectively whereas propranolol decreased the heart rate and minoxidil, when given alone, markedly increased the heart rate. Again propranolol significantly (P < 0.05) potentiated minoxidil hypotension (24% decrement in blood pressure) and prevented the associated tachycardia.
Removal of the source of renin by nephrectomy potentiated hydralazine- (Fig. 5) and particularly minoxidil- (Fig. 6 ) induced hypotension. However, nephrectomy did not alter the tachycardia caused by either vasodilator. The hydralazine hypotension after nephrectomy (43%) was comparable to that with the combination of propranolol and hydralazine (39%). Minoxidil (41%) and hydralazine (39%) hypotension after nephrectomy were comparable, but the blood pressure lowering with the minoxidil-propranolol combination (24%) was only about one-half that of minoxidil and nephrectomy. Blockade of the vasoconstrictor effects of angiotensin with the selective angiotensin antagonist saralasin resulted in potentiation of hydralazine (Fig. 7) and minoxidil (Fig. 8) hypotension. Further studies were done in another group of rats to determine whether the effect of propranolol was additive to that of saralasin in potentiating hydralazine hypotension. The results in Fig. 9 show that saralasin (10 mg/kg) alone had no effect on blood pressure or heart rate. Again, hydralazine lowered blood pressure (10%) with a concomitant increase in heart rate. This hypotension was potentiated with propranolol (18%) which also blocked the tachycardia. Saralasin and hydralazine caused a greater decrease in blood pressure (26%) than the propranolol-hydralazine combination, and the tachycardia pattern was similar to Renin and Vasodilatory Drug Hypotension that of hydralazine alone. Pretreatment with both saralasin and propranolol before hydralazine did not cause greater blood pressure lowering (25%) than with saralasin pretreatment alone. The smaller percent decrease in blood pressure with hydralazine noted here compared with Fig. 3 appears to be due to biological variation between groups of rats as in patients. This is the reason that each rat was used as its own control in each group of experiments. Biochemical studies with genetically hypertensive rats. The same pattern of blockade of hydralazine-induced renin release as seen in the normotensive rat (8) was observed in the genetically hypertensive rat (Table I). Hydralazine (1 mg/kg) resulted in a fourfold increase in SRA, and propranolol pretreatment (1.5 mg/kg) blocked 95% of this increase.
Hemodynamic studies with genetically hypertensive rats. Results similar to those obtained with the normotensive (Fig. 9 ) rats were observed when the same drug combinations were administered to genetically hypertensive rats (Fig. 10) . In the latter case, hydralazine (1 mg/kg) caused a 17% decrease in mean arterial pressure (MAP) whereas propranolol had an initial pressor effect (10.2%) which was followed by a gradual decrease in blood pressure (3.2% at 60 min). Saralasin alone (10 mg/kg) caused a significant decrement (7.4%) in blood pressure at one time period (55 min). When the rats were pretreated with propranolol and then given hydralazine, propranolol significantly potentiated (28.9% blood pressure decrease) the hypotension elicited by hydralazine. Saralasin pretreatment initially potentiated hydralazine hypotension more than propranolol, but after 35 min there was no significant difference between propranolol plus hydralazine (28.9%) and salalasin plus hydralazine (34.3%) despite the fact that the saralasin-hydralazine averages were less (approximately 10 mm Hg) than those of propranolol-hydralazine treatment.
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Heart rate was not recorded during the different drug treatments since MAP was being measured in the genetically hypertensive rat. DISCUSSION Angiotensin has multiple sites of pharmacologic action including central nervous system-mediated cardiac stimulation (11) (12) (13) , sympathetic neuronal activation (14) (15) (16) (17) , and the well-known vascular and adrenal effects.
Each of these pharmacologic actions contributes qualitatively to blood pressure elevation. The increment in SRA caused by vasodilating drugs significantly increases the levels of circulating angiotensin (18) . This increment would be expected to antagonize or limit the hypotensive action of vasodilating drugs due to angiotensin's broad spectrum of activities as well as the dynamic relationship between angiotensin and vasodilators at the vascular smooth muscle sites of action (19) . In these experiments with normotensive rats, impairment of renin release by propranolol was associated with marked potentiation of vasodilatory drug-induced hypotension. This observation is consistent with the hypothesis that increased angiotensin levels limit the effectiveness of systemic vasodilators, but it should be kept in mind that propranolol also blocks reflex cardiac stimulation. It has been suggested that the antihypertensive activity of propranolol alone may result from reduced cardiac output (20) , but this mechanism of action has been criticized (21). Since we did not measure cardiac outputs in these experiments, the possibility that this potentiation by propranolol is due in part to its negative inotropic and chronotropic cardiac effects cannot be eliminated. Propranolol also may contribute by a central nervous system mechanism (22-24) to blood pressure reduction. Although propranolol accentuated the hypotension following both vasodilators, the potentiation due to hydralazine appeared to be more pronounced than that due to minoxidil. It is unknown whether this observation is related to chronologic differences in blood pressure depression and renin release by the two agents.
Removal of the renin source by prior bilateral nephrectomy resulted in marked potentiation of hydralazine-and minoxidil-induced hypotension. This remarkable potentiation is consistent with the idea that the increment in angiotensin formed from elevated SRA antagonized a major component of the hypotensive activity of the vasodilating drugs. Absence of urinary excretion of hydralazine (25) , and minoxidil (26), however, could aslo contribute to this enhanced activity.
The marked tachycardia remaining after nephrectomy suggests that the cardiac stimulation precipitated by these vasodilating drugs is not dependent on angiotensinmediated central nervous system effects since the renin source is absent. This result also implies that blockade of the cardiac stimulation by propranolol is not the major potentiating mechanism of propranolol to the blood pressure decrement since this decrement occurred in presence of the tachycardia in nephrectomized animals.
Since propranolol can block both inotropic and chronotropic responses and since there is the possibility for error resulting from altered drug excretion following nephrectomy, our hypothesis was tested more specifically by using the selective angiotensin antagonist, saralasin (27) . Saralasin potentiated hydralazine hypotension without altering the pattern of cardiac stimulation. Additionally, impairment of renin release with propranolol pretreatment did not induce blood pressurelowering greater than the pretreatment with saralasin. The greater efficacy of saralasin pretreatment is no doubt due to the fact that it is competitively blocking the smooth muscle receptor for angiotensin. Even though propranolol is quite efficient in blocking renin release with hydralazine (91% at this propranolol dose, see reference 8), the small increment in angiotensin remaining may express some pharmacologic actvity. Thus, it is not surprising that a combined pretreatment with saralasin and propranolol could not potentiate hydralazine hypotension more than saralasin pretreatment alone.
Persistence of vasodilatory drug-induced tachycardia in nephrectomized and in saralasin-pretreated animals indicates that the cardiac stimulation is not dependent on central nervous system effects of angiotensin. A possible explanation is that saralasin did not have access to, or was ineffective in blocking an angiotensin receptor in the brain. However, this possibility seems unlikely since a peptide pharmacologically similar (1-Sar-8-Ile-angiotensin II) to saralasin has previously been shown to block centrally mediated angiotensin stimulation in dogs (28) Qualitatively similar results were obtained in biochemical (Table I ) and hemodynamic ( Fig. 10 ) studies with genetically hypertensive rats. Propranolol, in a dose known to cause a 20-fold displacement to the right of the isoproterenol (tachycardia) dose-response curve in normotensive rats (8) , blocked 95% of the renin release elicited by hydralazine (Table I) in the genetically hypertensive rat. In the normotensive rat, this dose of propranolol impaired 91% of the hydralazine-induced rise in SRA (8) . Thus the impairment of vasodilatory drug-induced renin release is essentially the same in normotensive and genetically hypertensive rats.
If the results of the hemodynamic experiments with normotensive ( Fig. 9 ) and genetically hypertensive (Fig. 10 ) rats are compared, a similar pattern of blood pressure decrement and potentiation was observed when propranolol or saralasin treatment preceded hydralazine.
Scriabine, Ludden, and Bohidar (31) recently reRenin and Vasodilatory Drug Hypotension ported potentiation of hydralazine hypotension using the beta adrenergic-blocking drug timolol, but failed to show similar potentiation by propranolol, in the genetically hypertensive rat. However, there were important technical differences from the studies reported here. Propranolol and hydralazine were administered orally in their studies. Both drugs are rapidly metabolized in the liver, particularly with the first dose or with low portal venous concentrations (32, 33) . This technical difference could explain the variable presence of tachycardia in their hydralazine controls. In our experiments propranolol was administered subcutaneously, and effectiveness of the beta adrenergic blockade was confirmed along with measurements of propranolol blood levels (8) . Also, we administered hydralazine parenterally and found rapid and consistent effects on blood pressure and heart rate. Alternatively, Scriabine, Ludden, and Bohidar (31) reported only the maximal blood pressure decrement noted during a 24-h period. These technical differences may have resulted in their failure to demonstrate propranolol's potentiating effect.
A major side effect of treatment with antihypertensive vasodilators is reflex sympathetic stimulation resulting in increased heart rate and cardiac output (1-4). Propranolol was originally combined with vasodilators (it was known to possess some antihypertensive activity of its own [22, 34, 35] ) to mitigate these untoward effects, but even greater benefit was gained from the combined drug treatment since the hypotensive efficacy of the vasodilator was increased (1) . Biihler, Laragh, Baer, Vaughn, and Brunner's (36) recent evidence that suppression of renin release with propranolol correlated with the hypotensive effect of propranolol alone, is consistent with the thesis that potentiation of vasodilator drug hypotension by propranolol may operate via this mechanism.
